Riolan's muscle: action and indications for botulinum toxin injection

Area of Science:

• Ophthalmology
• Neurology
• Medical Aesthetics

Background:

• Essential blepharospasm and hemifacial spasm are debilitating conditions often managed with botulinum toxin injections.
• Conventional periorbital injections have been the standard treatment, but efficacy and side effects can vary.
• Riolan's muscle, a component of the orbicularis oculi, has been explored as a potential target for improved treatment outcomes.

Purpose of the Study:

• To evaluate the efficacy and patient preference of botulinum toxin injections into Riolan's muscle for essential blepharospasm (typical and palpebral forms) and hemifacial spasm.
• To compare this new injection technique with conventional periorbital injections.
• To assess the dosage and cost-effectiveness of the Riolan's muscle injection method.

Main Methods:

• A study involving patients with typical essential blepharospasm (n=6), palpebral essential blepharospasm (n=4), and hemifacial spasm (n=30).
• Patients received botulinum toxin injections targeting Riolan's muscle at the medial and lateral aspects of the upper eyelids.
• Comparison was made with prior treatments using conventional bilateral periorbital injections.

Main Results:

• A majority of patients with typical essential blepharospasm (5/6) and all patients with palpebral essential blepharospasm preferred Riolan's muscle injections.
• Significant improvement was noted in palpebral form patients, with previously limited eye opening improving.
• Most hemifacial spasm patients (26/30) also preferred the Riolan's injections, with a considerably lower overall toxin dosage required compared to conventional methods.

Conclusions:

• Injections into Riolan's muscle represent a preferred treatment for all forms of blepharospasm and hemifacial spasm.
• This technique demonstrates superior patient preference and potentially improved outcomes, especially for palpebral blepharospasm.
• The Riolan's muscle injection method is more cost-effective due to reduced botulinum toxin requirements.